Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

Acquired byAstraZeneca
Price$443M
Date5/2013

General Information

Websiteomthera.com
CategoryBioTech
Phone908-741-4399
Employees
DescriptionClinical Stage BioPharma Company

Offices

Headquarters

People

President & CEO, Board Member, Co-Founder
Board of Directors
Board Member
Chief Medical Officer, Co-Founder
Executive Vice President and CFO
Board Observer

Funding

TOTAL $42.6M
FUNDING TOTAL $42.6M
Venture Round, 11/2009
$2.16M
Series A, 3/2010
Sofinnova Partners
$6.5M
Series B, 3/2011
New Enterprise Associates
Sofinnova Partners
$33.9M
DEBT TOTAL $17.6M
Debt, 2/2013
$17.6M

Tags

Omthera Pharmaceuticals

Omthera Pharmaceuticals, Inc. is an emerging specialty pharmaceuticals company focusing its efforts on the clinical development of new therapies for dyslipidemia. Led by a team of experts with exceptional experience in developing new therapies for lipid disorders, Omthera is dedicated to developing innovative therapies for the millions of patients who have elevated triglyceride levels and increased risk of cardiovascular disease.

Recent Milestones

Videos

Screenshots

Omthera Pharmaceuticals screenshot
Above: Omthera Pharmaceuticals
Uploaded: 3/15/11

Sources

  1. AstraZeneca to acquire Omthera Pharmaceuticals including NDA-ready novel dyslipidemia treatment to complement cardiovascular portfolio (worldpharmanews.com) [edit]
  2. SEC (sec.gov) [edit]
  3. Omthera Pharmaceuticals, Inc.: Series A $6.5M (onbiovc.com) [edit]
  4. Omthera rounds up $34M in Series B, adds David Mott to board (fiercebiotech.com) [edit]
  5. SEC (sec.gov) [edit]
Edit This Page
Last Edited 4/9/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize ยป

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy